RANGE IMPACT, INC.
RNGE evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RNGE—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RNGE
Range Impact, Inc. is a development-stage biotech company focused on glycosylated cannabinoid research and intellectual property, currently facing significant liquidity constraints and a going-concern risk.
Key risk: Going-concern risk
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 1 pipeline candidate for RANGE IMPACT, INC..
Range Impact, Inc. is a development-stage biotech company focused on glycosylated cannabinoid research and intellectual property, currently facing significant liquidity constraints and a going-concern risk.
- Cash & equivalents of $0.6M as of 2026-06-30 [sec].
- Total revenue of $1.1M and net loss of -$1.9M for the period ending 2026-06-30 [sec].
- Shareholders' equity of $21.5M and total debt of $1.6M as of 2026-06-30 [sec].
- Accumulated deficit of $56,879,882 as of December 31, 2024 [sec_mda · as of 2025-03-31].
- The company has performed 23 animal studies on glycosylated cannabinoids and holds a portfolio of related patents [sec_mda · as of 2024-08-14].
What works
- The company holds a portfolio of intellectual property for glycosylated cannabinoids, which it believes has significant value [sec_mda · as of 2024-08-14].
- Range Impact has conducted 23 animal studies on its glycosylated cannabinoids, generating favorable scientific data to refine its drug development plan [sec_mda · as of 2024-08-14].
What to weigh
- The company has a going-concern risk, with management stating it may not have sufficient funds to operate over the next 12 months [sec_mda · as of 2026-08-12].
- Cash & equivalents are only $0.6M as of 2026-06-30, with a net loss of -$1.9M for the period [sec].
- Accumulated deficit reached $56,879,882 as of December 31, 2024, reflecting sustained losses [sec_mda · as of 2025-03-31].
- The company's ability to continue as a going concern depends on raising additional capital, which is uncertain [sec_mda · as of 2026-05-15].
From the filings
Quoted directly from source documents.
The company may not have sufficient funds to operate over the next 12 months.
“Management has evaluated the Company's liquidity and capital resources for the twelve-month period from the date of issuance of these unaudited interim financial statements a”
SEC MD&A · August 12, 2026
The company has an accumulated deficit of $56.9 million.
“As of December 31, 2024, we had an accumulated deficit of $56,879,882.”
SEC MD&A · March 31, 2025
The company has performed 23 animal studies on glycosylated cannabinoids.
“Our research team has performed 23 animal studies to test the safety, efficacy and dosing levels of our glycosylated cannabinoids”
SEC MD&A · August 14, 2024
The company holds a portfolio of patents for glycosylated cannabinoids.
“We believe our intellectual property portfolio of glycosylated cannabinoids possess significant value”
SEC MD&A · August 14, 2024
Risks & what to watch (4)›
Key risks
- Going-concern risk — Management states the company may not have sufficient funds to operate over the next 12 months [sec_mda · as of 2026-08-12].
- Low cash reserves — Cash & equivalents of only $0.6M as of 2026-06-30, with ongoing net losses [sec].
- Dependence on additional financing — The company needs to raise additional capital to continue operations, which is uncertain [sec_mda · as of 2026-05-15].
- Accumulated deficit — Accumulated deficit of $56.9 million as of December 31, 2024, reflecting sustained losses [sec_mda · as of 2025-03-31].
What to watch
- Ability to raise additional capital to fund operations and avoid scaling back [sec_mda · as of 2026-08-12].
- Progress of glycosylated cannabinoid research and any new patent filings [sec_mda · as of 2024-08-14].
- Changes in cash position and net loss in future financial reports [sec].
- Any updates on the company's ability to continue as a going concern [sec_mda · as of 2026-05-15].
Sources: News · SEC MD&A · Generated August 27, 2026 · How we verify sources →
Run RANGE IMPACT, INC. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available RANGE IMPACT, INC. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
1.8 months
D/E 3.92 · 0% dilution
Lead: Preclinical
1 candidate
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Frequently asked questions
What is the AI investment thesis for RANGE IMPACT, INC.?
Range Impact, Inc. is a development-stage biotech company focused on glycosylated cannabinoid research and intellectual property, currently facing significant liquidity constraints and a going-concern risk.
What is RANGE IMPACT, INC.'s lead drug candidate?
RANGE IMPACT, INC.'s most advanced tracked candidate is vbx-100 (Preclinical) for Inflammatory conditions of the gastrointestinal tract.
Who is the CEO of RANGE IMPACT, INC.?
Mr. Michael R. Cavanaugh CPA, J.D. is the chief executive officer of RANGE IMPACT, INC. (RNGE).
Where is RANGE IMPACT, INC. headquartered?
RANGE IMPACT, INC. (RNGE) is headquartered in Cleveland, OH, United States.
What therapeutic areas does RANGE IMPACT, INC. focus on?
RANGE IMPACT, INC. develops therapies across Gastroenterology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.